Skip to main content

Advertisement

SpringerLink
Log in

Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients

  • Letter to the Editor
  • Published:
Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival. A systematic review and meta-analysis. JAMA Oncol. 2016;. doi:10.1001/jamaoncol.2015.5932.

    Google Scholar 

  2. Dahlen T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia. A population-based cohort study. Ann Intern Med. 2016;165(3):161–6.

    Article  PubMed  Google Scholar 

  3. Aichberger KJ, Herndihofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.

    Article  CAS  PubMed  Google Scholar 

  4. Breccia M, Colafigli G, Molica M, et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100–1.

    Article  CAS  PubMed  Google Scholar 

  5. Breccia M, Molica M, Zacheo I, et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular disease during nilotinib treatment. Ann Hematol. 2015;94:393–7.

    Article  CAS  PubMed  Google Scholar 

  6. Rea D, Mirault T, Raffoux E, et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia. 2015;29:1206–9.

    Article  CAS  PubMed  Google Scholar 

  7. Nishimura K, Okamura T, Watanabe M, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb. 2014;21:784–98.

    Article  PubMed  Google Scholar 

Download references

Funding

No specific funding was obtained to support the conduct of this study.

Author information

Authors and Affiliations

  1. Department of Hematology, Yokohama Municipal Citizen’s Hospital, 56 Okazawacho, Hodogaya-ku, Yokohama, 240-8555, Japan

    Yuki Osada, Hideki Arakaki, Satoshi Takanashi, Chisako Ito, Yoshinobu Aisa & Tomonori Nakazato

Authors
  1. Yuki Osada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Arakaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Takanashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chisako Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshinobu Aisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomonori Nakazato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomonori Nakazato.

Ethics declarations

Conflict of interest

All authors have no potential conflicts of interest to report.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patients. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Osada, Y., Arakaki, H., Takanashi, S. et al. Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients. Med Oncol 34, 66 (2017). https://doi.org/10.1007/s12032-017-0922-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-0922-5

Keywords

Search

Navigation